CANASA Drug Patent Profile

Which patents cover Canasa, and when can generic versions of Canasa launch?

Canasa is a drug marketed by Abbvie and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirteen patent family members in twelve countries.

The generic ingredient in CANASA is mesalamine. There are twenty-eight drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Canasa

A generic version of CANASA was approved as mesalamine by PADAGIS ISRAEL on September 17^th, 2004.

Summary for CANASA

International Patents:	13
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	181
Clinical Trials:	2
Drug Prices:	Drug price information for CANASA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CANASA
What excipients (inactive ingredients) are in CANASA?	CANASA excipients list
DailyMed Link:	CANASA at DailyMed

See drug prices for CANASA

See drug sales revenues for CANASA

Recent Clinical Trials for CANASA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sandoz	Phase 3
Forest Laboratories	Phase 3
Axcan Pharma	Phase 3

See all CANASA clinical trials

Pharmacology for CANASA

Drug Class

Aminosalicylate

Paragraph IV (Patent) Challenges for CANASA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CANASA	Suppository	mesalamine	1000 mg	021252	1	2013-05-24

US Patents and Regulatory Information for CANASA

CANASA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	CANASA	mesalamine	SUPPOSITORY;RECTAL	021252-002	Nov 5, 2004	AB	RX	Yes	Yes	8,217,083		Y
Abbvie	CANASA	mesalamine	SUPPOSITORY;RECTAL	021252-002	Nov 5, 2004	AB	RX	Yes	Yes	8,436,051		Y
Abbvie	CANASA	mesalamine	SUPPOSITORY;RECTAL	021252-001	Jan 5, 2001		DISCN	No	No

International Patents for CANASA

See the table below for patents covering CANASA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2010339837	Mesalamine suppository
South Africa	201204422	MESALAMINE SUPPOSITORY
Chile	2012001636	Supositorio rectal de mesalamina , en donde las particulas de mesalamina tienen un area de superficie de 0,1 m2/g a 1,3 m2/g, util en el tratamiento de proctitis ulcerosa activa.
Japan	2013514979

CANASA Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Canasa

Introduction to Canasa

Canasa, a brand-name suppository containing the active ingredient mesalamine, is prescribed for ulcerative proctitis in adults. Understanding the market dynamics and financial trajectory of Canasa involves examining the broader pharmaceutical market, particularly the segments related to gastrointestinal treatments and the impact of generic alternatives.

Pharmaceutical Market Overview in Canada

Canada's pharmaceutical market is significant, with a 2.2% share of the global market, making it the 8th largest worldwide. The market has seen positive compound annual growth since 2017, at a rate of 6.4%[4].

Brand-Name vs. Generic Drugs

In Canada, brand-name products account for 80.5% of pharmaceutical sales by value but only 25.7% of prescriptions by quantity. Generic drugs, on the other hand, account for 19.5% of market sales by value and a substantial 74.3% of the market share by prescriptions[4].

Generic Alternatives and Cost Implications

Canasa has a generic equivalent, mesalamine suppository, which is considered as safe and effective as the brand-name version but generally costs less. The availability of generic alternatives significantly impacts the financial trajectory of brand-name drugs like Canasa.

• Cost Comparison: Generic drugs, including mesalamine suppositories, tend to be more cost-effective than their brand-name counterparts. This cost difference can influence patient and prescriber preferences, potentially reducing the market share of Canasa[5].

• Market Impact: The expiration of patents for high-profile branded drugs, such as Canasa, allows generic manufacturers to enter the market. This has been a pivotal driver in the growth of the generic drug market in Canada, which is projected to grow from US$9.7 billion in 2023 to US$19.2 billion by 2032, with a CAGR of 7.9%[3].

Financial Assistance and Savings Programs

For patients using Canasa, the cost can vary based on several factors, including treatment plans, insurance coverage, and the pharmacy used. Financial assistance programs and savings coupons, such as those offered by Optum Perks, can help reduce the cost of Canasa prescriptions.

• Insurance Coverage: The cost of Canasa with insurance can be significantly lower than without it. Patients should consult their insurance providers to understand the coverage and any out-of-pocket costs[5].

• Savings Programs: Many pharmaceutical companies offer savings programs for their brand-name drugs. For Canasa, exploring these programs or using coupons can help patients save money on their prescriptions[5].

Market Trends and Projections

The Canadian pharmaceutical market, including the segment for gastrointestinal treatments like Canasa, is influenced by several trends:

• Chronic Disease Prevalence: An increase in chronic diseases, including gastrointestinal conditions, drives the demand for medications like Canasa. This trend is expected to continue, supporting the growth of the pharmaceutical market[3].

• Government Initiatives: Proactive government initiatives and policy-driven incentives promote the use of generic drugs, which can impact the sales of brand-name drugs. However, these initiatives also ensure that patients have access to affordable and effective treatments[3].

• Healthcare Infrastructure: Improvements in healthcare infrastructure and distribution channels enhance access to medications, including both brand-name and generic versions of drugs like Canasa[3].

Financial Trajectory

The financial trajectory of Canasa is likely to be influenced by the following factors:

• Generic Competition: The presence of generic mesalamine suppositories will continue to pressure the pricing and market share of Canasa. As more patients opt for the generic version, the sales of Canasa may decline[3][5].

• Healthcare Expenditure: The overall expenditure on pharmaceuticals in Canada is increasing, with total pharmaceutical sales rising by 56.4% from 2012 to 2021. However, the specific expenditure on Canasa will depend on its market positioning and competition from generics[4].

• Clinical Value and Patient Preferences: The clinical value and patient preferences will also play a role. If Canasa is perceived to offer significant benefits over its generic counterpart, it may retain a loyal patient base, despite the cost difference[2].

Key Takeaways

• Generic Competition: The availability of generic mesalamine suppositories significantly impacts the market share and pricing of Canasa.
• Financial Assistance: Patients can benefit from financial assistance programs and savings coupons to reduce the cost of Canasa prescriptions.
• Market Trends: The Canadian pharmaceutical market is driven by increasing chronic disease prevalence, government initiatives, and improvements in healthcare infrastructure.
• Financial Trajectory: The sales of Canasa are likely to be influenced by generic competition, overall healthcare expenditure, and clinical value.

FAQs

1. What is the main difference between Canasa and its generic equivalent? The main difference is the cost; generic mesalamine suppositories are generally cheaper than the brand-name Canasa but are considered equally safe and effective.

2. How does insurance coverage affect the cost of Canasa? Insurance coverage can significantly reduce the out-of-pocket cost of Canasa. Patients should check their insurance plans to understand the coverage and any associated costs.

3. What are some ways to save money on Canasa prescriptions? Patients can use savings programs, coupons like those from Optum Perks, and opt for the generic version of the drug to save money.

4. How is the Canadian pharmaceutical market expected to grow in the coming years? The Canadian pharmaceutical market, including the generic drug segment, is projected to grow with a CAGR of 7.9% from 2023 to 2032, driven by factors such as increasing chronic disease prevalence and government initiatives.

5. What impact do government initiatives have on the sales of brand-name drugs like Canasa? Government initiatives promoting the use of generic drugs can reduce the market share and sales of brand-name drugs like Canasa by making generic alternatives more appealing due to their cost-effectiveness.

Sources

1. Oncology Medicines in Canada: Trends and International Comparisons - Canada.ca
2. Cost and value of cancer medicines in a single-payer public health system - PubMed
3. Insights Into the Generic Drugs Market in Canada - GlobeNewswire
4. Pharmaceutical industry profile - ised-isde.canada.ca
5. Canasa Cost 2024: Savings Tips and More - MedicalNewsToday